Englander Institute for Precision Medicine

Publications

Found 14 results
Author Title Type [ Year(Asc)]
Filters: Author is Puca, Loredana  [Clear All Filters]
2023
Van Emmenis L, Ku S-Y, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V et al..  2023.  The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.. Cancer Res Commun. 3(8):1447-1459.
2022
Tang F, Xu D, Wang S, Wong CKhuan, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K et al..  2022.  Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.. Science. 376(6596):eabe1505.
Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, Asad M, Martin MLaura, Sigouros M, Rowdo FM et al..  2022.  Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.. Adv Mater. 34(2):e2100096.
2021
Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku S-Y, Puca L, Zhu Y et al..  2021.  Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.. Nat Commun. 12(1):6377.
2020
Cyrta J, Augspach A, De Filippo MRosaria, Prandi D, Thienger P, Benelli M, Cooley V, Bareja R, Wilkes D, Chae S-S et al..  2020.  Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.. Nat Commun. 11(1):5549.
2019
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)
Puca L, Vlachostergios PJ, Beltran H.  2019.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.. Cold Spring Harb Perspect Med. 9(2)
Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
2018
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
2017
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
2016
Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.